Despite treatment advances in hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC), patients still experience reduced health-related quality of life (HRQoL). This study investigated concordance between patient-physician reported symptoms and side effects, and the impact of reporting on HRQoL among patients with HR+/HER2- mBC. Data were derived from the Adelphi Real World Advanced Breast Cancer Disease Specific Programme (DSP)™, a cross-sectional survey of physicians and their patients with HR+/HER2- mBC receiving treatment, conducted in Europe and the United States between August 2022 and February 2023. Physicians reported patient characteristics, symptoms and side effects. Patients reported symptoms, side-effects and HRQoL using validated instruments. Descriptive, linear regression, and patient-physician concordance analyses were performed. Overall, 298 physicians provided data on 1,642 patients, of which 321 patients self-reported data. Tiredness (85.6
HER2-positive breast cancer is a distinct subtype associated with less favorable outcomes without targeted therapy. Dual HER2 blockade with pertuzumab and trastuzumab has shown improved efficacy compared to single-agent approaches, but results across studies remain variable. This meta-analysis aims to evaluate the overall efficacy and safety of pertuzumab-based regimens. A systematic search of PubMed, Scopus, Web of Science, and the Cochrane Library was conducted to identify relevant RCTs. The quality of trials was assessed using the ROB-2 tool, and the certainty of the evidence was assessed using the GRADE tool. Data were synthesized using R. This study included 8 RCTs with 8367 patients. Pertuzumab-based regimens were associated with improved overall survival. In the locally advanced or metastatic setting, a pronounced benefit was observed (HR = 0.71, 95
Disease recurrence after definitive therapy remains a major cause of morbidity and mortality in early-stage breast cancer, with limited options for treatment intensification. Cell surface–targeted (CST) therapies, including antibody-drug conjugates (ADCs), radiopharmaceuticals, and immune-based approaches, have demonstrated success in treating malignancies. However, the known CST repertoire in breast cancer is narrow, largely restricted to HER2 and TROP2, highlighting an unmet need for novel targets in treatment-resistant disease. We profiled CST expression using large-scale gene expression datasets annotated with clinical outcomes, including SCAN-B (n ≈ 10,000), aggregated neoadjuvant chemotherapy cohorts (n ≈ 4,000), and the randomized SWEBCG91RT trial (n = 765). CSTs with therapies in clinical trials were prioritized. RNA-protein correlation was assessed using CPTAC and SCMP datasets. Associations with recurrence-free survival (RFS) and treatment response were analyzed using Cox regression and Fisher’s exact test with Benjamini-Hochberg correction. Of 78 CSTs under active clinical investigation, RNA expression strongly predicted protein expression (median accuracy 80–94
Data on the risk factors that increase the risk of brain metastases (BM) in breast cancer is lacking. Mining the prospectively collected data of adjuvant studies for BM at first recurrence may identify a population for prevention strategies. Data collected from 7 sequential adjuvant studies conducted by the Hellenic Cooperative Oncology Group was queried for recurrence in CNS. Parameters associated with the development of BMs at first recurrence were collected. 5,318 patients were included. After a median follow-up time of 137.0 months (range, 0-334.1), the iBCFS at 120 months was 73.2
Male breast cancer is rare, and data on its clinicopathological and germline characteristics remain scarce. Our objective was to describe the clinicopathological profile of men with breast cancer and to estimate the prevalence of pathogenic germline variants in cancer predisposition genes. This multicenter retrospective study included adult men diagnosed with breast cancer between January 2000 and June 2022 at two institutions. Clinical and pathological data were obtained from medical records. Germline analysis was performed in patients without prior testing using DNA from biobanks or saliva samples and a custom multigene panel. A total of 106 patients were included. Median age at diagnosis was 58.5 years (range, 33–84), and 64
